乳腺癌术后子宫内膜病变影响因素分析
回顾性分析212例乳腺癌术后因子宫内膜病变行妇科手术患者的临床病理资料,发现异常子宫出血和子宫内膜增厚是发生子宫内膜癌的独立危险因素;子宫内膜厚度≥0.49 cm时预测子宫内膜癌的敏感度为78%、特异度为25%;SERM治疗组子宫内膜厚度显著高于AI组和未治疗组,但复发率和二次手术率组间无显著差异。
要点
- 异常子宫出血和子宫内膜增厚是乳腺癌术后发生子宫内膜癌的独立危险因素。
- 子宫内膜厚度≥0.49 cm预测子宫内膜癌的敏感度为78%、特异度为25%。
- SERM治疗者子宫内膜厚度显著高于AI组和未治疗组,复发率及二次手术率组间无显著差异。
核心结论
- 异常子宫出血和子宫内膜增厚是乳腺癌患者术后发生子宫内膜癌的危险因素。
- 子宫内膜厚度对乳腺癌患者术后发生子宫内膜癌具有预测价值。
- SERM治疗可增加乳腺癌术后患者的子宫内膜厚度,同时增加子宫内膜病变复发率及二次手术率。
研究设计与样本
- 回顾性研究,纳入2006年6月至2018年1月浙江大学医学院附属妇产科医院212例乳腺癌术后因子宫内膜病变行妇科手术治疗的患者。
主要发现
- 子宫内膜病变严重程度与有无异常子宫出血及子宫内膜厚度有关(P<0.05)。
- 异常子宫出血、子宫内膜增厚是乳腺癌患者术后发生子宫内膜癌的独立危险因素(P<0.05)。
- 子宫内膜厚度阈值≥0.49 cm时预测子宫内膜癌的敏感度为78%,特异度为25%。
- 妇科手术后SERM治疗组子宫内膜厚度为(0.56±0.39)cm,显著高于AI组(0.33±0.23)cm和未治疗组(0.44±0.28)cm(P<0.05)。
- SERM组子宫内膜病变复发率26.2%、二次手术率14.3%,AI组分别为9.5%、4.8%,未治疗组分别为21.6%、4.9%,分别比较差异均无统计学意义(P>0.05)。
关键数值与推荐
- 子宫内膜厚度≥0.49 cm作为预测子宫内膜癌的截断值,敏感度78%、特异度25%。
- SERM组子宫内膜厚度(0.56±0.39)cm vs AI组(0.33±0.23)cm vs 未治疗组(0.44±0.28)cm(P<0.05)。
- SERM组复发率26.2%、二次手术率14.3%;AI组复发率9.5%、二次手术率4.8%;未治疗组复发率21.6%、二次手术率4.9%(分别比较P>0.05)。
临床怎么用
- 对乳腺癌术后患者,应关注异常子宫出血症状及子宫内膜厚度,以评估子宫内膜癌风险。
- 子宫内膜厚度≥0.49 cm时需警惕子宫内膜癌可能,但特异度较低。
- SERM治疗期间需监测子宫内膜厚度变化及子宫内膜病变复发。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To study influencing factors which cause the endometrial diseases in patients with breast cancer after operation. Methods: A retrospective study was performed on 212 breast cancer post-operation patients with endometrial diseases between June 2006 and January 2018 in Women's Hospital School of Medicine Zhejiang University to analyse the factors which influenced the endometrial diseases. Results: The abnormal uterine bleeding and endometrial thickness were related to the severity of endometrial disease in patients with breast cancer, and they were independent risk factors for breast cancer patients to have endometrial cancer (P<0.05) . When the diagnostic cut off value of endometrial thickness was ≥0.49 cm, the sensitivity and specificity to endometrial cancer were 78% and 25%, respectively. The average endometrial thickness was (0.56±0.39) cm in patients who were treated by selective estrogen receptor modulator (SERM) after gynecological surgery, which was significantly thicker than that of aromatase inhibitor (AI) group [ (0.33±0.23) cm] and no treatment group [ (0.44±0.28) cm, P<0.05]. The endometrial disease recurrent rate and reoperation rate in SERM group were (26.2%, 14.3%) slightly higher than that of AI group (9.5%, 4.8%) and no treatment group (21.6%, 4.9%), but there were not significant differences (all P>0.05). Conclusions: The clinical symptom of abnormal uterine bleeding and thickening endometrium are risk factors for breast cancer patients to have endometrial cancer. The endometrial thickness has high predictive value for breast cancer patients to diagnose endometrial cancer. The SERM treatment increases the endometrial thickness, recurrent rate and reoperation rate in post-operation patients. 目的: 探讨乳腺癌患者术后发生子宫内膜病变的影响因素。 方法: 收集2006年6月—2018年1月浙江大学医学院附属妇产科医院收治的因乳腺癌术后发生子宫内膜病变进行相关妇科手术治疗的212例患者的临床病理资料,回顾性分析乳腺癌患者术后发生子宫内膜病变的影响因素。 结果: 乳腺癌患者术后发生的子宫内膜病变的严重程度与患者有无异常子宫出血及子宫内膜厚度有关(P<0.05),异常子宫出血、子宫内膜增厚是影响乳腺癌患者术后发生子宫内膜癌的独立危险因素(P<0.05)。当子宫内膜厚度≥0.49 cm时,预测子宫内膜癌的敏感度为78%,特异度为25%。子宫内膜息肉术后接受选择性ER调节剂治疗患者的子宫内膜厚度[(0.56±0.39)cm]显著高于接受芳香酶抑制剂治疗患者[(0.33±0.23)cm]及未治疗患者[(0.44±0.28)cm,P<0.05];选择性ER调节剂治疗患者的子宫内膜病变复发率及二次手术率(分别为26.2%、14.3%)高于芳香酶抑制剂治疗患者(分别为9.5%、4.8%)及未治疗患者(分别为21.6%、4.9%),但分别比较,差异均无统计学意义(P>0.05)。 结论: 有异常子宫出血、子宫内膜增厚是乳腺癌患者术后发生子宫内膜癌的高危因素。子宫内膜厚度对乳腺癌患者术后发生子宫内膜癌具有良好的预测价值。子宫内膜息肉患者术后接受选择性ER调节剂治疗可使子宫内膜增厚,同时增加子宫内膜病变的复发率及二次手术率。.
引用
- Pan NP, Zhou WX, Tang J, et al. [Analysis of influencing factors of endometrial disease of patients with breast cancer after operation]. Zhonghua Fu Chan Ke Za Zhi. 2019. PMID: 31874475. doi:10.3760/cma.j.issn.0529-567x.2019.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。